

Disclosure

- Advisory board Novartis
- Speaker for AOP Health
- Speaker for pharma&

Werner Zinkand

PV-Patient diagnosed in 2011

Chair of Steering Committee since 2020

Global MPN Advocates Network



MPN Horizons

Understanding the
New Complexity of MPNs





13-15 October
Zagreb, Croatia

2023.



Novel Agents Beyond RUXO: MPNs 2023 and Beyond

- **PV**
 - Ropeginterferon (FDA approved Nov 2021)
 - PTG-300(Rusfertide-hepcidin mimetic)
- **ET**
 - Ropeginterferon
 - Bomedemstat (po LSD-1 inhibitor)
- **SM**
 - Avapritinib, Bezuclostinib (APEX), other KIT inhibitors
- **8p11 /FGFR MLNs**
 - Pemigatinib
 - Fight-203 phase 2
 - FDA approved Aug 26, 2022: R/R Myeloid/Lymphoid Neoplasms (MLN) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement
- **MF**
 - **Novel JAKi beyond RUXO and FEDR:**
 - Pacritinib (PAC): FDA approved Feb 28, 2022 int/high-risk MF with plt count <50
 - Momelotinib (MOMENTUM ph 3)
 - NS-018, other JAKi
 - **Novel JAKi + combos →R Phase 3**
 - BCLxLi + RUXO
 - BRDi/BETi + RUXO
 - **Completely novel agents beyond JAKi in R/R MF**
 - **Anemia in MF: New mechanisms/new agents: ACVR1 and beyond**

 **IACH**  **COLYM**  **COMyDAL**  **MPN Co&D**
The joint COMyDAL, COLYM, MPNCo&D and 6th Annual Meeting
of the International Academy for Clinical Hematology (IACH)
October 5-7, 2023 – Paris, France & Online




IACH COLYM COMVAL MPN Co&D
 MydAL, COLYM, MPNCo&D and 6th Annual Meeting
 National Academy for Clinical Hematology (IACH)
 October 5-7, 2023 – Paris, France & Online



Ph I/II Combinations: JAKi + another agent/ “add-back or add-on” for MF

- RUXO + AZA – frontline (MF) and MDS/MPN-U
 – MDACC : MF (Masarova et al BLOOD 2018)
- RUXO + HSP90i (MF)
 – ClinicalTrials.gov Identifier: NCT03373877
- RUXO + BCL-xLi (MF) (Navitoclax)
 – ClinicalTrials.gov Identifier: NCT03222609
- RUXO + PI3Ki (MF) (Parsaclisib)
 – ClinicalTrials.gov Identifier: NCT01730248
- RUXO + THAL (MF) - frontline & R/R
 – ClinicalTrials.gov Identifier: NCT03069326
- RUXO + HDACi (Pracinostat) (MF) – frontline
- RUXO + IFN (2 ongoing clinical trials – Europe)
- RUXO + BETi (MF) (Pelabresib)
- RUXO + Sotatercept /Luspatercept
- RUXO + XPO1 / Selinexor (low dose, po weekly + RUXO)
- RUXO + MDM2i



Economides M, Verstovsek S, Pemmaraju N Curr Hematol Malig Rep. 2019 A

What is the mpn-advocates-net?

MPN AN is the place where international organizations meet that represent MPN patients.



34 / 43



Who is here for the first time?



Thank you to our Sponsors

Initiating Platinum Sponsor



Gold Sponsor



Silver Sponsor



Bronze Sponsor



